Autopsy report · NCT01428505

[18F]PBR111 and Microglial Activation in Multiple Sclerosis

Cause of deathOther Automatic label, confidence 0.3, unverified. How labels are made.

“The Study was terminated because there was insufficient data to complete the study objectives”

The sponsor’s own words in the registry.

Life of this trial

Registered 2 months after it had already started.
Ran for about 1 year 8 months before it stopped.
50 participants enrolled.
No results are posted on the registry.

Vital statistics

Status: Terminated
Phase: Phase 2
Sponsor: GlaxoSmithKline
Sponsor type: Industry
Conditions: Multiple Sclerosis
Interventions: [18F]PBR111
Participants: 50
Sites: 1
Countries: United Kingdom

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.